A Phase 4 interventional study of Winlevi (clascoterone) 1% & Duac gel in Acne Vulgaris, sponsored by Sun Pharmaceutical Industries Limited. Completed at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-07-17.
Sponsored by Sun Pharmaceutical Industries Limited · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing clascoterone in Acne Vulgaris — 5 open to participants now, 7 under way, 2 of them phase 3. Clascoterone · Acne Vulgaris.
Among the 19 studies testing clascoterone in Acne Vulgaris, this one is the 17th largest by enrollment, is one of 4 that started in 2023, is one of 7 in phase 4, and was the 8th registered.
791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.
Browse Acne Vulgaris studies →5 of the 19 studies testing clascoterone in Acne Vulgaris are open now, in 2 countries. Recruiting first, the newest first:
Pak Emirates Military Hospital · Sites in Pakistan
Ages 12–55
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd. · Sites in China
Ages 12+
Allied Hospital Faisalabad · Sites in Pakistan
Ages 15+
Khyber Teaching Hospital
Ages 12–35
Zhejiang Sunshine Mandi Pharmaceutical Co.,Ltd.
Ages 12+
By country, each count listing its studies:
Clascoterone: first FDA approval 2020 (WINLEVI), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 5 · Phase 4 7
First in 2012; this study’s year is marked. 4 started in 2023.
This study's enrollment of 10 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 50 across the 19 interventional studies. Of the 12 that completed or were terminated, 11 (92%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 19 have an industry lead sponsor. The 8 most frequent:
Sun Pharmaceutical Industries Limited is the lead sponsor of 60 studies on the registry; 5 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 22 (92%) have results posted.
30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited: none open now, 1 under way, none of them phase 3. Of 29 finished, 8 (28%) have results posted.
Among the 30 studies in Acne Vulgaris by Sun Pharmaceutical Industries Limited, this one is the 28th largest by enrollment, is one of 5 that started in 2023, is one of 7 in phase 4, and was the 22nd registered.
Sun Pharmaceutical Industries Limited’s Acne Vulgaris studies by the year they started, since 2007.
3 of the studies testing clascoterone in Acne Vulgaris that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07673094Khyber Teaching HospitalComparison of Topical Clascoterone and Adapalene for Mild Acne Vulgaris | 2027-02 |
| NCT07883538Pak Emirates Military HospitalComparison of Topical Clascoterone 1% Cream Versus Adapalene 0.1% Cream in the Treatment of Mild-to-Moderate Acne Vulgaris | 2027-04-30 |
| NCT07881315Allied Hospital FaisalabadClascoterone Versus Clindamycin Added to Adapalene/Benzoyl Peroxide for Moderate Facial Acne | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 19 studies testing clascoterone in Acne Vulgaris, from their registry updates:
Among Sun Pharmaceutical Industries Limited’s 30 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Duac gel in combination to emulate real life practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
i. Outpatient, male or female subjects of any race, and at least 12 years of age or older.
A female is considered of childbearing potential unless she is:
Reliable methods of contraception are:
ii. Facial acne IGA score of 3 or 4.
iii. Able to understand the requirements of the study and sign /HIPAA Authorization forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian.
Exclusion Criteria:
i. Female subjects who are pregnant (positive urine pregnancy test), breast-feeding, or who are of and not practicing a reliable method of .
ii. Allergy or sensitivity to any component of the test medications. iii. Subjects who have not complied with the proper for prohibited medications .
iv. Medical condition that, in the opinion of the Investigator, contraindicates the subject's participation in the clinical study.
v. Skin disease/disorder that might interfere with the diagnosis or evaluation of acne vulgaris vi. Evidence of recent alcohol or drug abuse. vii. History of poor cooperation, non-compliance with medical treatment, or unreliability.
viii. Exposure to an drug study within 30 days of the Baseline Visit.
ix. Patients who have demonstrated (e.g., anaphylaxis) to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. (4) • Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (including pseudomembranous colitis)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Winlevi (clascoterone) 1% & Duac gel
Participants will use Winlevi (clascoterone) 1% and Duac gel as per label
The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16.
The investigator will evaluate global acne severity using the Investigator Global Assessment scale, which ranges from 0 to 5, where 0 represents clear skin and 5 represents very severe acne
Time frame: Week 16
Percent of Total Lesion Reduction at Week 16 Compared to Baseline
Time frame: Week 16
Percent of Inflammatory Lesion Reduction at Week 16 Compared to Baseline
Time frame: Week 16
Percent of Non-inflammatory Lesion Reduction at Week 16 Compared to Baseline.
Time frame: Week 16
Tolerability Measures of Erythema Based on 5-point Severity Scale
The score in the scale ranges from 0-4. Lower score represents absence of erythema and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" erythema at weeks 4,8,12 and 16
Time frame: Week 4,8,12,16
Tolerability Measures of Dryness Based on 5-point Severity Scale
The score in the scale ranges from 0-4. Lower score represents absence of dryness and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" dryness at weeks 4,8,12 and 16.
Time frame: Week 4,8,12,16
Tolerability Measures of Peeling Based on 5-point Severity Scale
The score in the scale ranges from 0-4. Score 0 represents absence of peeling and Score 4 represents 'Extensive peeling'. The information presented represents the "Percentage of participant" with "Absent or Trace" peeling at weeks 4,8,12 and 16
Time frame: Week 4,8,12,16
Assessment of Skin Oiliness Based on 5-point Severity Scale
The score in the scale ranges from 0-4. Score 0 represents absence of Oiliness and Score 4 represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" oiliness at weeks 4,8,12 and 16
Time frame: Week 4,8,12,16
Tolerability Measures of Burning/Stinging Based on 6-point Severity Scale
The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" burning at weeks 4,8,12 and 16
Time frame: Week 4,8,12,16
Tolerability Measures of Pruritus Based on 6-point Severity Scale
The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" Pruritus at weeks 4,8,12 and 16
Time frame: Week 4,8,12,16
| Milestone | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Started | 10 |
| Completed | 9 |
| Not completed | 1 |
The investigator will evaluate global acne severity using the Investigator Global Assessment scale, which ranges from 0 to 5, where 0 represents clear skin and 5 represents very severe acne
| Percentage of patients | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| The Primary Endpoint of This Study is the Percent of Patients Who Achieve Clear or Almost Clear on Investigator Global Assessment (IGA) Scale at Week 16. | 100 |
| Percent change | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Percent of Total Lesion Reduction at Week 16 Compared to Baseline | 92 ± 8.2 |
| Percent change | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Percent of Inflammatory Lesion Reduction at Week 16 Compared to Baseline | 96.4 ± 6 |
| Percent change | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Percent of Non-inflammatory Lesion Reduction at Week 16 Compared to Baseline. | 86.1 ± 15.3 |
The score in the scale ranges from 0-4. Lower score represents absence of erythema and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" erythema at weeks 4,8,12 and 16
| Percentage of participant | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Baseline | 66 (31 to 91) |
| Week 4 | 88 (51 to 99) |
| Week 8 | 88 (51 to 99) |
| Week 12 | 88 (51 to 99) |
| Week 16 | 100 (63 to 100) |
The score in the scale ranges from 0-4. Lower score represents absence of dryness and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" dryness at weeks 4,8,12 and 16.
| Percentage of participant | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Baseline | 100 (63 to 100) |
| Week 4 | 100 (63 to 100) |
| Week 8 | 100 (63 to 100) |
| Week 12 | 100 (63 to 100) |
| Week 16 | 100 (63 to 100) |
The score in the scale ranges from 0-4. Score 0 represents absence of peeling and Score 4 represents 'Extensive peeling'. The information presented represents the "Percentage of participant" with "Absent or Trace" peeling at weeks 4,8,12 and 16
| percentage of participants | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Baseline | 100 (63 to 100) |
| Week 4 | 100 (63 to 100) |
| Week 8 | 100 (63 to 100) |
| Week 12 | 100 (63 to 100) |
| Week 16 | 100 (63 to 100) |
The score in the scale ranges from 0-4. Score 0 represents absence of Oiliness and Score 4 represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" oiliness at weeks 4,8,12 and 16
| percentage of participants | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Baseline | 100 (63 to 100) |
| Week 4 | 100 (63 to 100) |
| Week 8 | 100 (63 to 100) |
| Week 12 | 100 (63 to 100) |
| Week 16 | 100 (63 to 100) |
The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" burning at weeks 4,8,12 and 16
| percentage of participants | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Baseline | 100 (63 to 100) |
| Week 4 | 100 (63 to 100) |
| Week 8 | 88 (51 to 99) |
| Week 12 | 100 (63 to 100) |
| Week 16 | 100 (63 to 100) |
The score in the scale ranges from 0-5. Lower score represents absence of discomfort and higher score represents severe condition. The information presented represents the "Percentage of participant" with "Absent or Trace" Pruritus at weeks 4,8,12 and 16
| percentage of partiicipants | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Baseline | 100 (63 to 100) |
| Week 4 | 100 (63 to 100) |
| Week 8 | 100 (63 to 100) |
| Week 12 | 88 (51 to 99) |
| Week 16 | 100 (63 to 100) |
Collected over 16 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Winlevi (Clascoterone) 1% & Duac Gel | 0/9 (0%) | 0/9 (0%) | 0/9 (0%) |
| Age, Continuous(years) | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Mean | 33 ± 17 |
| Sex: Female, Male(Participants) | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| Female | 5 |
| Male | 4 |
| Race (NIH/OMB)(Participants) | Winlevi (Clascoterone) 1% & Duac Gel |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 5 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2023 to primary completion in Jul 2024, 7 months.
Results were first posted in Jul 2025, 1 year after primary completion.
Of 45 phase 4 interventional studies under Acne Vulgaris, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 16. This study's 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clascoterone
Sun Pharmaceutical Industries Limited →